X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to expand and accelerate Ikena’s targeted oncology programs, including both IK-930, a TEAD1 selective Hippo pathway inhibitor, and IK-595, a MEK-RAF complexing inhibitor.
Lead Product(s): IK-930
Therapeutic Area: Oncology Product Name: IK-930
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pionyr Immunotherapeutics
Deal Size: $43.0 million Upfront Cash: $43.0 million
Deal Type: Financing August 07, 2023
Details:
Through the acquisition, Ikena gains all of Pionyr’s assets including, PY314 and PY159, targeting TREM2 and TREM1 respectively, which are designed to selectively deplete and in some cases reprogram certain tumor-associated macrophages responsible for immunosuppression.
Lead Product(s): PY314,Pembrolizumab
Therapeutic Area: Oncology Product Name: PY314
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Pionyr Immunotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 07, 2023
Details:
The Company anticipates the net proceeds to further its ongoing clinical development of targeted oncology programs, including IK-930, a novel TEAD inhibitor for the treatment of cancers in phase 1 clinical trial and IK-595, a MEK-RAF complex inhibitor.
Lead Product(s): IK-930
Therapeutic Area: Oncology Product Name: IK-930
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: TD Cowen
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 15, 2023
Details:
IK-175 targets AHR, a compelling cancer-driving transcription factor that prevents immune recognition in a multitude of cancers by modulation of innate and adaptive immunity.
Lead Product(s): IK-175,Nivolumab
Therapeutic Area: Oncology Product Name: IK-175
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
IK-595, a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor has been nominated as the company’s first development candidate in the RAS pathway.
Lead Product(s): IK-595
Therapeutic Area: Oncology Product Name: IK-595
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
IK-930 is an oral, paralog-selective TEAD inhibitor targeting the Hippo signaling pathway. IK-930 binds to TEAD transcription factors and prevents transcription of multiple genes that drive cancer progression.
Lead Product(s): IK-930,Undisclosed
Therapeutic Area: Oncology Product Name: IK-930
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
IK-930 is an oral, paralog-selective TEAD inhibitor targeting the Hippo signaling pathway. IK-930 binds to TEAD transcription factors and prevents transcription of multiple genes that drive cancer progression.
Lead Product(s): IK-930
Therapeutic Area: Oncology Product Name: IK-930
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
IK-175 is an AHR (a compelling cancer-driving transcription factor) antagonist designed to modulate the tumor microenvironment, increasing both innate and adaptive immunity and offers a new opportunity for patients who cannot benefit from current standard-of-care treatments.
Lead Product(s): IK-175,Nivolumab
Therapeutic Area: Oncology Product Name: IK-175
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
IK-930 binds to TEAD transcription factors to prevent transcription of multiple genes in Hippo pathway that are known to cause cancer progression, provide a novel targeted approach to address underlying biology driven by the genetic alterations that cause cancer pathogenesis.
Lead Product(s): IK-930
Therapeutic Area: Oncology Product Name: IK-930
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
IK-930 is an oral, selective TEAD inhibitor targeting Hippo signaling pathway, binds to TEAD transcription factors and prevents transcription of multiple genes that drive cancer progression and IK-175 is a selective, oral small molecule Aryl Hydrocarbon Receptor inhibitor.
Lead Product(s): IK-930
Therapeutic Area: Oncology Product Name: IK-930
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
